EN | UA
EN | UA

Help Support

Back

An update on the effectiveness of baricitinib in the treatment of RA

An update on the effectiveness of baricitinib in the treatment of RA An update on the effectiveness of baricitinib in the treatment of RA
An update on the effectiveness of baricitinib in the treatment of RA An update on the effectiveness of baricitinib in the treatment of RA

What's new?

Treatment with bDMARDs should be initiated in patients showing inadequate response to CsDMARDs. Barcitinib as monotherapy as well as in combination with CsDMARDs was found effective in treating RA.

Baricitinib with advantages like oral administration, rapidity of action, efficacy in monotherapy and over adalimumab in one study and non-immunization found efficacious in rheumatoid arthritis (RA) treatment. In the past decades, improvement has been seen in the outcome for rheumatoid arthritis patients, but appropriate control of disease cannot be achieved in a substantial proportion of patients. Newly available drugs having the novel mechanism of action could be an added value to the current armamentarium.
This review concentrate on the pharmacodynamics and pharmacokinetics of baricitinib. Moreover, the article summarizes and comments on the drug's efficacy and safety profile in RA patients.

Baricitinib is available for oral administration. It is a targeted synthetic JAK1 and JAK2 inhibitor. Baricitinib either as monotherapy, or is given in combination with conventional synthetic (cs) DMARDs, has revealed its efficacy with an acceptable safety profile in early active RA naive to DMARDs, and active RA with an inadequate response to csDMARDs and/or biologic (b)DMARDs.

The future status of baricitinib for the management of RA patients will depend on several factors. Additional long-term safety data will influence prescribing decisions.

Source:

Expert Opin Pharmacother. 2017 Jul 24

Article:

Efficacy of baricitinib in the treatment of rheumatoid arthritis

Authors:

Richez C, Truchetet ME et. al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: